Search results for "OUTCOME"

showing 10 items of 5148 documents

Neuroprotective effect of erythropoietin and darbepoetin alfa after experimental intracerebral hemorrhage.

2009

OBJECTIVE: Intracerebral hemorrhage (ICH) is a devastating clinical syndrome for which no truly efficacious therapy has yet been identified. In preclinical studies, erythropoietin (EPO) and its long-lasting analog, darbepoetin alfa, have been demonstrated to be neuroprotective in several models of neuronal insult. The objectives of this study were to analyze whether the systemic administration of recombinant human EPO (rHuEPO) and its long-lasting derivative darbepoetin alfa expedited functional recovery and brain damage in a rat model of ICH. METHODS: Experimental ICH was induced in rats by injecting autologous blood into the right striatum under stereotactic guidance. Subsequently, animal…

Brain InfarctionMaleDarbepoetin alfaBrain EdemaBrain damageNeuroprotectionDrug Administration ScheduleCentral nervous system diseaseRats Sprague-DawleyBlood Transfusion AutologousErythropoietin; Erythropoietin derivative; Intracerebral hemorrhage; Neuroprotectionhemic and lymphatic diseasesEdemamedicineAnimalsHumansDarbepoetin alfaErythropoietinCerebral HemorrhageIntracerebral hemorrhagebusiness.industryBasal Ganglia HemorrhageBrainmedicine.diseaseNeuroprotectionCorpus StriatumRecombinant ProteinsRatsErythropoietin derivativeDisease Models AnimalNeuroprotective AgentsTreatment OutcomeErythropoietinAnesthesiaErythropoietin Erythropoietin derivative Intracerebral hemorrhage NeuroprotectionSystemic administrationHematinicsSurgeryNeurology (clinical)medicine.symptomIntracerebral hemorrhagebusinessmedicine.drugNeurosurgery
researchProduct

Caspase-dependent cell death involved in brain damage after acute subdural hematoma in rats

2006

Abstract Traumatic brain injury is associated with acute subdural hematoma (ASDH) that worsens outcome. Although early removal of blood can reduce mortality, patients still die or remain disabled after surgery and additional treatments are needed. The blood mass and extravasated blood induce pathomechanisms such as high intracranial pressure (ICP), ischemia, apoptosis and inflammation which lead to acute as well as delayed cell death. Only little is known about the basis of delayed cell death in this type of injury. Thus, the purpose of the study was to investigate to which extent caspase-dependent intracellular processes are involved in the lesion development after ASDH in rats. A volume o…

Brain InfarctionMalePathologymedicine.medical_specialtyTraumatic brain injuryIschemiaApoptosisBrain damageNeuroprotectionAmino Acid Chloromethyl KetonesBrain IschemiaRats Sprague-DawleyLesionIn Situ Nick-End LabelingmedicineAnimalsHematoma Subdural AcuteEnzyme InhibitorsSubdural spaceMolecular BiologyIntracranial pressurebusiness.industryVascular diseaseGeneral Neurosciencemedicine.diseaseRatsDisease Models AnimalBloodNeuroprotective AgentsTreatment Outcomemedicine.anatomical_structureBrain InjuriesCaspasesAnesthesiaNeurology (clinical)Intracranial Hypertensionmedicine.symptombusinessSignal TransductionDevelopmental BiologyBrain Research
researchProduct

Monitoring brain activity in preterms: mathematics helps to predict clinical outcome: Figure 1

2015

Brain activity and meditationTreatment outcomeNeurology (clinical)PsychologyOutcome (game theory)Developmental psychologyBrain
researchProduct

Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H…

2020

Abstract Objectives Given a lack of universally-accepted standard-of-care treatment for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), study objectives were to assess treatment utilization and survival outcomes for R/M HNSCC in the real-world setting. Materials and methods A multi-site retrospective chart review was conducted in Europe (Germany, United Kingdom, Italy, Spain), Asia Pacific (Australia, South Korea, Taiwan), and Latin/North America (Brazil and Canada) to identify patients who initiated first-line systemic therapy for R/M HNSCC between January 2011 and December 2013. Patients were followed through December 2015 to collect clinical characte…

Bridged-Ring CompoundsMaleCanadaCancer Researchmedicine.medical_specialtymedicine.medical_treatmentTaiwanMedizinCetuximabPlatinum CompoundsKaplan-Meier EstimateSystemic therapy03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsRepublic of KoreaConfidence IntervalsmedicineHumans030223 otorhinolaryngologySurvival analysisAgedRetrospective StudiesChemotherapyCetuximabSquamous Cell Carcinoma of Head and Neckbusiness.industryHead and neck cancerAustraliaMiddle Agedmedicine.diseaseHead and neck squamous-cell carcinomaConfidence intervalEuropeRegimenMethotrexateTreatment OutcomeOncologyHead and Neck Neoplasms030220 oncology & carcinogenesisFemaleTaxoidsFluorouracilNeoplasm Recurrence LocalOral SurgerybusinessBrazilmedicine.drugOral Oncology
researchProduct

Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma.

2007

An inhaled corticosteroid (ICS) or an ICS/long-acting beta(2)-agonist (LABA) combination plus short-acting beta(2)-agonist (SABA) as needed for symptom relief is recommended for persistent asthma. Additionally, budesonide/formoterol maintenance and reliever therapy (Symbicort SMART, AstraZeneca, Sweden) has been approved for adults in the European Union. This option is well tolerated and offers greater reductions in asthma exacerbations together with similar improvements in daily symptom control, at a lower overall steroid load, compared with fixed-dose ICS/LABA plus SABA.Two large clinical trials investigated the use of budesonide/formoterol as maintenance and reliever compared with medium…

BudesonideAdultMalemedicine.medical_specialtyAdolescentlaw.inventionPlacebosRandomized controlled trialDouble-Blind MethodlawInternal medicineFormoterol Fumaratemedicinemedia_common.cataloged_instanceHumansAnti-Asthmatic AgentsEuropean unionBudesonidemedia_commonAsthmaAgedRandomized Controlled Trials as TopicAged 80 and overbusiness.industryGeneral MedicineAdrenergic beta-AgonistsMiddle Agedmedicine.diseaseClinical trialTreatment OutcomeBudesonide/formoterolEthanolaminesPhysical therapyFormoterol FumarateDrug Therapy CombinationFemaleFormoterolbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugCurrent medical research and opinion
researchProduct

Routine Use of Budesonide/Formoterol Fixed Dose Combination in Elderly Asthmatic Patients: Practical Considerations

2017

Asthma has been demonstrated to be as common in the elderly as in younger age groups. Although no specific recommendations exist to manage the disease differently in older individuals, functional features and clinical presentations may be affected by age per se, and by age-related conditions, such as comorbidities and polypharmacy. In this review article, we aimed to explore the efficacy and safety in elderly asthmatic patients of one of the most currently used inhaled treatments for asthma, that is, the fixed-dose combination of budesonide/formoterol. We attempted to address some practical questions that are relevant to the daily practice of clinicians. We focused on the efficacy and real-…

BudesonideGeriatrics & GerontologyDatabases Factuallaw.invention0302 clinical medicineRandomized controlled trialRELIEVER THERAPYlawBudesonide Formoterol Fumarate Drug CombinationDrug InteractionsPharmacology (medical)Anti-Asthmatic AgentsPharmacology & Pharmacy030212 general & internal medicineEMPHYSEMATOUS LUNGSGeriatricsPRIMARY-CAREGeriatrics and Gerontology Pharmacology (medical)Middle AgedRANDOMIZED CONTROLLED-TRIALSINGLE INHALERTreatment OutcomeDrug InteractionPractice Guidelines as TopicLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialtySettore MED/10 - Malattie Dell'Apparato RespiratorioOBSTRUCTIVE PULMONARY-DISEASE03 medical and health sciencesAdministration InhalationmedicineAnti-Asthmatic AgentHumansOLDER-PEOPLEIntensive care medicineAgedAsthmaPolypharmacyAIRWAY CLEARANCEScience & Technologybusiness.industryDRY POWDER INHALERSmedicine.diseaseAsthma030228 respiratory systemBudesonide/formoterolLUNG DEPOSITIONGeriatricsPhysical therapyIndacaterol1115 Pharmacology And Pharmaceutical SciencesFormoterolGeriatrics and GerontologybusinessDrugs & Aging
researchProduct

Safety Considerations of Inhaled Corticosteroids in the Elderly

2014

Inhaled corticosteroids (ICSs) are widely used in the treatment of patients with chronic obstructive pulmonary diseases. However, high-dose regimens and long-term use of ICSs have the potential to cause a variety of local and systemic side effects such as candidiasis, cataracts, glaucoma, and osteoporosis. The use of ICSs can also be associated with the risk of bone fractures, diabetes mellitus and pneumonia. These ICS-related side effects are of particular importance in elderly patients due to the presence of comorbidities and age-related behavioral, cognitive, and psychological problems, which can all interact with inhaled treatment. We reviewed the available literature on the clinically …

Budesonidemedicine.medical_specialtyOsteoporosisSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionatePulmonary Disease Chronic ObstructivePharmacotherapyCataractsAdrenal Cortex HormonesDiabetes mellitusAdministration InhalationmedicineHumansPharmacology (medical)asthma corticosteroidsIntensive care medicineAgedCOPDbusiness.industrymedicine.diseaseAsthmaPneumoniaTreatment OutcomePhysical therapyGeriatrics and Gerontologybusinessmedicine.drugDrugs & Aging
researchProduct

Medical management of Crohn's disease

2011

The medical approach to Crohn's disease has been modified in recent years thanks to the introduction of new therapies, like biologics. Also, well-designed studies and systematic reviews have allowed better evaluation of the role of old drugs like steroids and immunosuppressors. This review aims to evaluate the recent evidence on the medical approach to Crohn's disease in the different settings of the disease.Randomized controlled trials and meta-analyses were included in the review. The research on all the studies discussed was based on the Cochrane Library, Medline and Embase, using the following medical subject headings: Crohn's disease, clinical trial, therapy, 5-aminosalicylic acid, ste…

Budesonidemedicine.medical_specialtyPathologyAnti-Inflammatory AgentsMEDLINEDiseaseCochrane LibraryManagement of Crohn's diseaselaw.inventionCrohn DiseaseRandomized controlled trialAdrenal Cortex HormoneslawmedicineHumansPharmacology (medical)BudesonideIntensive care medicineBone Marrow TransplantationPharmacologyBiological ProductsTumor Necrosis Factor-alphabusiness.industryRemission InductionGeneral Medicinemedicine.diseaseAnti-Bacterial AgentsIntestinesClinical trialAminosalicylic AcidsMethotrexateTreatment OutcomeSystematic reviewPurinesbusinessImmunosuppressive Agentsmedicine.drugExpert Opinion on Pharmacotherapy
researchProduct

Development and validation of the neighborhood environment walkability scale for youth across six continents

2019

Abstract Background The IPEN International Physical Activity and Environment Network Adolescent project was conducted using common study protocols to document the strength, shape, and generalizability of associations of perceived neighborhood environment attributes with adolescents’ physical activity and overweight/obesity using data from 15 countries. Countries did not use identical versions of the Neighborhood Environment Walkability Scale for Youth (NEWS-Y) to measure perceived neighborhood environment attributes. Therefore, this study derived a measurement model for NEWS-Y items common to all IPEN Adolescent countries and developed a scoring protocol for the IPEN Adolescent version of t…

Built environmentHealth BehaviorMedicine (miscellaneous)WalkingCardiovascularAdolescentsMedical and Health SciencesACCESSIBILITYDevelopmental psychology0302 clinical medicineResidence CharacteristicsSurveys and QuestionnairesMedicine and Health SciencesSOCIOECONOMIC-STATUS030212 general & internal medicinelcsh:RC620-627Built environmentPediatricNutrition and Dieteticslcsh:Public aspects of medicineIPEN ADULTGlobal16. Peace & justiceConfirmatory factor analysisStrokelcsh:Nutritional diseases. Deficiency diseasesWalkabilityScale (social sciences)HEALTH OUTCOMESRELIABILITYPublic Health0305 other medical sciencePsychologyBEHAVIORPediatric Research InitiativeAdolescentPARTICIPATIONeducationPhysical Therapy Sports Therapy and RehabilitationPooled analysesConfirmatory factor analysisEducation03 medical and health sciencesClinical ResearchBehavioral and Social ScienceMEASURED PHYSICAL-ACTIVITYHumansGeneralizability theoryObesityCategorical variableSocioeconomic statusExercise030505 public healthQuestionnairePreventionMethodologyConstruct validityReproducibility of Resultslcsh:RA1-1270social sciencesAdolescent BehaviorInternational Journal of Behavioral Nutrition and Physical Activity
researchProduct

Gestācijas svara pieauguma ietekme uz dzemdībām un jaundzimušo

2018

KOPSAVILKUMS Virsraksts: Gestācijas svara pieauguma ietekme uz dzemdībām un jaundzimušo Mērķis: Grūtniecība var būt vissvarīgākais fizioloģiskais process dzīves ciklā. Pareiza barošana grūtniecības un pēcdzemdību periodā ir svarīga gan jaundzimušo, gan mātes veselībai. Šī pētījuma mērķis ir analizēt saistību starp grūsnības ķermeņa masas pieauguma rādītājiem dažādās vecuma grupās un novērtēt neonatāla rezultāta ietekmi uz abiem bērniem. Materiāli un metodes: materiāls tika savākts no 2017. gada oktobra līdz 2017. gada decembrim Rīgas Dzemdību nams. Mēs iekļāvām 306 sievietes ar normālu jebkura vecuma un grūtniecības ķermeņa svaru, piemēram, priekšlaicīgu dzemdību laiku, termiņu un pēcnāves …

C-sectionNeonatal outcomesGestational weight gainDelivery outcomesMedicīnaMaternal age
researchProduct